Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: primary day-28 analysis of a phase 2/3 open-label study
Sign Up to like & getrecommendations! Published in 2024 at "Vaccine"
DOI: 10.1101/2024.10.25.24316129
Abstract: Background Most of the population has been infected with SARS-CoV-2 and, thus, is primed by natural exposure. As such, it was assessed whether a single dose of the monovalent XBB.1.5 vaccine, NVX-CoV2601, elicited a comparable… read more here.
Keywords: sars cov; xbb; vaccine; vaccine naive ... See more keywords